Message from harry zelatis on Nov 14 1996 10:20AM EST
The best thing to do is to ask for a package from immunex. This will tell us what
Immunex has in its pipeline as far as IL-1b is concerned.
///////////////////////////////////////////
Arrrggggghhhhh!!!! Harry......... Immunex has no remaining interest in IL-1beta or IL-1alpha as a product. None. Zip. Zero. Nichts. From the IMNX perspective (therapeutics), IL-1 is a dead product. CIST has IL-1beta license agreements, therapeutics-related, with Genetic Therapy Inc. (Sandoz) and the mystery company that licensed it 12/94. Perhaps one of these two companies does not agree with IMNX that IL-1beta is dead as a therapeutic. My own gut feeling is that the project is dead at GTI and would only come to life if an IMNR-like cancer vaccine project shows promise. None of us know who the "12/94" company is or if they have a going project. Time will tell, and maybe now Galton et al. will become more disclosure-oriented.
Harry...... you're driving me nuts. :-)
If IMNX had an ongoing, promising clinical interest with IL-1, CIST would now be trading at $10/share! That's why IMNX rolled over, and that's why I'm interested in the content of the patent claims that were assigned to CIST from IMNX...... I assume that the judge saw that the patents, relatively worthless to IMNX, had value for CIST's business development. Let's hope that the mystery "12/94" company has exactly that, a promising, on-going clinical program using IL-1beta. However, since the 10-K indicates that PAI-2 is in clinical trials, I'm focusing my attention there.
Cheers! Rick |
